A5039975788- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Helicobacter pylori-related gastroenterology studies
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Eosinophilic Esophagitis
- Inflammatory Biomarkers in Disease Prognosis
- Peptidase Inhibition and Analysis
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Multiple Myeloma Research and Treatments
- Galectins and Cancer Biology
- Monoclonal and Polyclonal Antibodies Research
- Economic and Financial Impacts of Cancer
- Ultrasound and Hyperthermia Applications
- Pancreatitis Pathology and Treatment
- Esophageal Cancer Research and Treatment
- Celiac Disease Research and Management
- Cancer Mechanisms and Therapy
- Viral-associated cancers and disorders
Military Medical Academy
2013-2024
University of Defence
2018-2024
Oncology Institute of Vojvodina
2002-2022
Ankara University
2002
The selective MEK1/2 inhibitor pimasertib has shown anti‐tumour activity in a pancreatic tumour model. This phase I/II, two‐part trial was conducted patients with metastatic adenocarcinoma (mPaCa) (NCT01016483). In the I part, oral given once daily discontinuously (5 days on/2 off treatment) or twice continuously ( n = 53) combined weekly gemcitabine (1,000 mg/m 2 ) 28‐day cycles to identify recommended II dose (RP2D) of pimasertib. were randomised placebo plus 88) investigate...
Oxaliplatin causes disabling acute and chronic peripheral neuropathy. We explored the preventive effects of calmangafodipir, mimicking mitochondrial enzyme manganese superoxide dismutase, thereby protecting cells from oxidative stress, in a placebo-controlled, double-blinded randomised phase II study (ClinicalTrials.gov.NCT01619423) patients with metastatic colorectal cancer (mCRC).mCRC treated modified FOLFOX-6 (folinic acid 200 mg/m2, 5-fluorouracil bolus 400 oxaliplatin 85 mg/m2 2400...
We assessed the treatment effect of panitumumab plus best supportive care (BSC) vs BSC on overall survival (OS) in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) and report first prospective extended RAS analysis a phase 3 trial. Patients mCRC were randomised 1 : to (6 mg kg−1 Q2W) or BSC. On-study crossover was prohibited. mutation status determined by central laboratory testing. The primary endpoint OS mCRC; (KRAS NRAS exons 2, 3, 4) secondary...
Namodenoson, an A3 adenosine-receptor agonist, showed promising results in advanced hepatocellular carcinoma (HCC) and moderate hepatic dysfunction (Child–Pugh B; CPB) a phase I/II clinical study. This II study investigated namodenoson as second-line therapy such patients. Patients were randomized 2:1 to twice day (BID) (25 mg; n = 50) or placebo (n 28). The primary endpoint (overall survival [OS]) was not met. Median OS 4.1/4.3 months for namodenoson/placebo (hazard ratio [HR], 0.82; 95%...
344 Background: In metastatic pancreatic cancer (mPaCa), KRAS mutations lead to constitutive activation of the MAPK pathway in vast majority cases. Pimasertib (Pim) is a selective, non-competitive MEK 1/2 inhibitor with potent antitumor activity preclinical models activation. Methods: Following phase I, dose-finding part trial, 88 patients (pts) mPaCa were randomized 1:1 receive Pim 60 mg BID (A, 44 pts) or placebo (B, combination weekly gemcitabine (Gem) 1000 mg/m 2 (7 8 wks cycle 1, then 3...
IntroductionTumor rat sarcoma gene (RAS) status is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). We analyzed outcomes according to RAS and v-Raf murine viral oncogene homolog B (BRAF) mutational status, evaluated early tumor shrinkage (ETS) depth of response (DpR) patients with wild type RAS.Patients MethodsPatients confirmed colon or rectum adenocarcinoma, Kristen exon 2 clinical/radiologic disease...
2503 Background: There is no established primary treatment for patients with advanced HCC and severe liver dysfunction (Child-Pugh B class; CPB), thus this representing a clear unmet need. Namodenoson, an A 3 AR agonist, showed promising preliminary results in population open label phase 1/2 clinical study (NCT00790218), median overall survival (OS) of 8.1 months. We present the double blind, randomized 2, placebo-controlled (NCT02128958), assessing efficacy safety namodenoson as second-line...
Liver resection is the gold standard in managing patients with metastatic or primary liver cancer. The aim of our study was to compare traditional clamp-crushing technique radiofrequency- assisted terms postoperative function.Liver function evaluated preoperatively and on days 3 7. synthetic parameters (serum albumin level, prothrombin time international normalized ratio), markers hepatic injury necrosis alanine aminotransferase, aspartate aminotransferase total bilirubin level) microsomal...
642 Background: An overall survival (OS) benefit in WT KRAS exon 2 mCRC was not seen with pmab monotherapy study 20020408 possibly due to crossover of patients (pts) the BSC arm. Retrospective analyses have indicated that other and NRAS mutations beyond are predictive anti-EGFR tx effects. Study 20100007 assesses OS chemorefractory is first phase 3 trial prospectively evaluate effects RAS (exons 2, 3, 4 NRAS) mCRC. Methods: Anti-EGFR naive pts were randomized 1:1 receive (6 mg/kg Q2W) + or...
10018 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major problem after oxaliplatin treatment. Calmangafodipir (CaM) has shown promising activities in model systems preventing oxaliplatin-induced adverse effects. In dose-escalating phase I study including 11 patients, doses up to 10 µmol/kg were well tolerated and had preventive effects on CIPN (Glimelius, MASCC 2015). A randomized placebo-controlled multicenter II (NCT 01619423) assessed safety efficacy of CaM...
Background: Bevacizumab is an anti-VEGF, humanized mAb that the most advanced agent of its class in clinical development. Several studies have examined bevacizumab combination with chemotherapy first- and second-line settings patients metastatic CRC. Despite that, there lack information concerning extent to which can be used treat We still need more evidence related efficacy safety different settings, or sequential treatments. The aim this study was investigate added Methods: This a...
To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide in mice with experimentally-induced inflammatory bowel disease.This study was designed as a controlled, animal, drug safety investigation. C57Bl/6 were used to establish ulcerative colitis model by exposure dextran sulfate sodium (DSS), divided into three experimental groups: eptifibatide-treated (150 µg/day intraperitoneally; n = 10), ticagrelol-treated (1 mg/day via gastric tube; DSS-control (plain...
The roles of carcinoembryonic antigen (CEA) and carbohydrate (CA19-9) in monitoring the patient response to chemotherapy for metastatic colorectal cancer (mCRC) are not clearly defined, inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte (LMR), platelet-to-lymphocyte (PLR) systemic immune-inflammation index (SII), have been sparsely investigated this purpose.To aim study was evaluate relationship between kinetics CEA, CA19-9, NLR, LMR, PLR SII serum...
Background/Aim. We designed and conducted this study due to the fact that results of previous studies about seroreactivity low-molecular-weight Helicobacter pylori antigens, cytotoxin-associated gene A (CagA), vacuolating cytotoxin (VacA) in patients with gastric cancer peptic ulcer were conflicting. Methods. The Western blot test was performed 123 patients, 31 cancer, duodenal ulcer, 30 gastritis functional dyspepsia order determine IgG antibodies H. antigens (CagA, VacA, Heat shock protein...
3536 Background: In the primary analysis of study 20100007, pmab + BSC significantly improved OS and PFS vs in WT KRAS exon 2 mCRC and, first prospective phase 3 study, RAS (exons 2, 3, 4 NRAS) mCRC. We report final evaluate BRAF status from 20100007. Methods: Anti-EGFR naïve patients (pts) with were randomized 1:1 to or BSC. On-study crossover was prohibited. assessed centrally. The endpoint mCRC; secondary endpoints safety both populations. Pts followed for survival ≥2 years after last pt...
3561 Background: Activating RAS mutation is a negative predictor of anti-EGFR therapy. In the final analysis 20100007, first phase 3 study to prospectively evaluate efficacy and safety WT ( KRAS NRAS exons 2, 3, 4 ) mCRC, pmab + BSC continued show improved survival (OS PFS) ORR. Recent data suggest that tumor burden reduction ETS may contribute OS. Previous studies have shown plus chemotherapy results in ETS, which correlates with OS benefit (Douillard et al, EJC, 2015; Rivera JCO, Mansmann...
Background/Aim. In our previous study, IgG seropositivities against Helicobacter (H) pylori antigens VacA, 50 kDa, 30 and 26 kDa were highlighted as biomarkers for the specific outcome of infection. We designed conducted this study in order to investigate whether synchronous and/or alternative seroreactivity H. patients with gastric cancer peptic ulcers exhibit stronger association than dyspepsia vice versa. Methods. determine antibodies antigens, a Western blot test was performed 123...
A subset of patients with non-Hodgkin's lymphoma (NHL) clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus any target lesion to judge the immediate effectiveness immediately applied additional treatment modalities.Since 1988 we have adopted in this single centre, prospective non-randomized study, a watch-and-wait policy such patients, who addition had non-bulky disease, normal LDH levels, no 'B'...